MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Epizyme Company Profile (NASDAQ:EPZM)

Consensus Ratings for Epizyme (NASDAQ:EPZM) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.50 (148.73% upside)

Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016JMP SecuritiesReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Leerink SwannReiterated RatingOutperform$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016MizuhoReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016RBC CapitalReiterated RatingOutperform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016WedbushReiterated RatingOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Citigroup Inc.Initiated CoverageBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015SunTrustInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Epizyme (NASDAQ:EPZM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q1($0.53)($0.41)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.65)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.59)($0.56)$5.42 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.70)($0.63)$2.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2015Q115($0.99)($1.75)$5.63 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.53)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.55)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.50)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.47)($0.22)$8.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Epizyme (NASDAQ:EPZM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.63)($0.42)($0.51)
Q2 20164($0.68)($0.45)($0.55)
Q3 20164($0.73)($0.49)($0.61)
Q4 20164($0.77)($0.52)($0.63)
Q1 20171($0.63)($0.63)($0.63)
Q2 20171($0.65)($0.65)($0.65)
Q3 20171($0.67)($0.67)($0.67)
Q4 20171($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)
Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Epizyme (NASDAQ:EPZM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Epizyme (NASDAQ:EPZM)
DateHeadline
06/23/16 05:57 AMEpizyme Inc. (EPZM) is Trading Lower on Unusual Volume for June 20 - Equities.com
06/23/16 05:57 AMEpizyme (EPZM), Genentech (RHHBY) Enter Collaboration for Tazemetostat and Tecentriq Trial in NHL - StreetInsider.com
06/23/16 05:57 AMEpizyme Inc. (EPZM) is Trading Lower on Unusual Volume for June 21 - Equities.com
06/22/16 03:57 PMEpizyme (EPZM), Genentech (RHHBY) Enter Collaboration for Tazemetostat and Tecentriq Trial in NHL
06/22/16 11:39 AMEpizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq™ (atezolizumab) for Treatment of Non-Hodgkin Lymphoma - [at noodls] - Clinical trial to evaluate Epizyme's clinical-stage EZH2 inhibitor in combination with anti-PD-L1 cancer immunotherapy CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage ...
06/21/16 03:38 PMWeekly Biotech Report Covering Epizyme Inc (EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd. (TEVA ... - Insider Monkey (blog)
06/21/16 07:35 AMEpizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : June 21, 2016 -
06/20/16 03:44 PMEpizyme (EPZM) Offers Prelim. Data from Tazemetostat Phase 2 in NHL; Favorable Safety Profile Noted
06/20/16 03:44 PMEpizyme to Continue Blood Cancer Trials as Tumors Were Wiped Out in Some Patients
06/20/16 03:44 PMWeekly Biotech Report Covering Epizyme Inc (NASDAQ:EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd. (NYSE:TEVA) drug Vantrela
06/20/16 02:22 PMWeekly Biotech Report Covering Epizyme Inc (EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd. (TEVA) Drug Vantrela -
06/20/16 10:04 AMEpizyme, Inc. (NASDAQ:EPZM) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 10:04 AMTrade-Ideas: Epizyme (EPZM) Is Today's Weak On High Relative Volume Stock - TheStreet.com
06/20/16 10:04 AMWeekly Biotech Report Covering Epizyme Inc (NASDAQ:EPZM) - Market Exclusive
06/20/16 08:05 AMEpizyme stock down 6% after worse than expected mid-phase trial results -
06/20/16 05:07 AMEPIZYME, INC. Files SEC form 8-K, Other Events -
06/20/16 01:48 AM2:48 am Epizyme reports early data from global Phase 2 trial of Tazemetostat demonstrating favorable safety profile consistent with prior clinical experience -
06/19/16 03:36 PMEpizyme Reports Data From Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma
06/19/16 06:59 AMEpizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting - [at noodls] - Tazemetostat demonstrates favorable safety profile consistent with prior clinical experience Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses ...
06/16/16 09:05 PMRecently Issued Stock Ratings For Epizyme, Inc. (NASDAQ:EPZM) - Fiscal Standard
06/16/16 02:30 PMRonald Muhlenkamp Sells JPMorgan, Morgan Stanley -
06/10/16 09:56 PMEpizyme Inc. (EPZM) Drops 5.62% on June 09 - Equities.com
06/10/16 03:57 PMEpizyme (EPZM): Today's Weak On High Volume Stock - TheStreet.com
06/09/16 07:56 AMEarnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy? -
06/08/16 09:57 PMEPIZYME INC. (NASDAQ:EPZM) Financial Condition Compared to S&P 500 - CML News
06/08/16 07:51 AMEpizyme Inc. (EPZM) Jumps 6.09% on June 06 - Equities.com
06/07/16 03:57 PMTrade-Ideas: Epizyme (EPZM) Is Today's Strong On High Relative Volume Stock - TheStreet.com
06/06/16 07:15 AMHow Many Epizyme Inc (NASDAQ:EPZM)'s Analysts Are Bullish? - HNN
06/06/16 07:15 AMPerformance Review for Epizyme, Inc. (NASDAQ:EPZM) - HNN
06/05/16 07:32 AMEcor1 Capital LLC Increased Epizyme INC (NASDAQ:EPZM) by $10.80 Million as Shares Declined - CCH Daily News
06/04/16 03:52 PMStocks within Analysts Screening: Epizyme, Inc. (NASDAQ:EPZM) , LDR Holding Corporation (NASDAQ:LDRH) - Street Updates
06/04/16 03:52 PMStocks within Analysts Screening: Epizyme, Inc. (NASDAQ:EPZM) , LDR Holding Corporation (NASDAQ:LDRH) - Street Updates
06/04/16 07:48 AMEpizyme Inc. (EPZM) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/03/16 04:05 PMSirius XM Holdings Inc. (NASDAQ:SIRI) decreased -0.25%: Epizyme, Inc. (NASDAQ:EPZM), Annaly Capital ... - KC Register
06/03/16 04:05 PMEpizyme, Inc. (NASDAQ:EPZM) Stock Update & Estimates - Stock Tick Tock
06/03/16 08:13 AMEpizyme Inc. (EPZM) Jumps 9.01% on June 02 - Equities.com - Epizyme Inc. (EPZM) Jumps 9.01% on June 02Equities.comEpizyme Inc. (EPZM) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 9.01% to $12.88, representing a gain of $1.065 per share. Some 475,813 shares traded hands on 3,850 trades, compared with an average ...and more »
06/01/16 10:09 PMEpizyme Inc. (EPZM) Jumps 6.83% on June 01 - Equities.com - Epizyme Inc. (EPZM) Jumps 6.83% on June 01Equities.comEpizyme Inc. (EPZM) was among the biggest gainers on the Russell 2000 for Wednesday June 01 as the stock popped 6.83% to $11.82, representing a gain of $0.755 per share. Some 827,934 shares traded hands on 6,281 trades, compared with an average ...and more »
06/01/16 02:24 PMEpizyme, Inc. :EPZM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 08:47 AMStock Review and Earnings Check on Epizyme, Inc. (NASDAQ:EPZM) - HNN - Stock Review and Earnings Check on Epizyme, Inc. (NASDAQ:EPZM)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Epizyme, Inc. (NASDAQ:EPZM) to ...and more »
05/31/16 08:47 AMNeothetics, Inc. (NASDAQ:NEOT) went down 6.78%: Epizyme, Inc. (NASDAQ:EPZM), Itau Unibanco Holding SA (ADR ... - KC Register - Neothetics, Inc. (NASDAQ:NEOT) went down 6.78%: Epizyme, Inc. (NASDAQ:EPZM), Itau Unibanco Holding SA (ADR ...KC RegisterEpizyme, Inc. (NASDAQ:EPZM) announced that data from four abstracts from the Company's clinical development program in support of tazemetostat for use in non-Hodgkin lymphoma (NHL) will be presented during the American Society of Hematology ...and more »
05/26/16 12:15 AMInsiders Are Gradually Buying Epizyme, Inc. (NASDAQ:EPZM) - Wall Street Hints and News - Insiders Are Gradually Buying Epizyme, Inc. (NASDAQ:EPZM)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Epizyme, Inc. (NASDAQ:EPZM) have increased their position in the stock by 118.88% over the past 6 months. Insiders now own 26.47% of total outstanding shares. There are both legal and illegal types of ...and more »
05/25/16 12:29 AMBroker Roundup For Epizyme, Inc. (NASDAQ:EPZM) - Share Trading News - Broker Roundup For Epizyme, Inc. (NASDAQ:EPZM)Share Trading News11/03/2014 – Epizyme, Inc. was downgraded to “neutral” by analysts at Zacks. They now have a USD 32.6 price target on the stock. The share price of Epizyme, Inc. (NASDAQ:EPZM) was up +1.76% during the last trading session, with a day high of 10.53.and more »
05/24/16 07:10 PMEarnings Review and Stock Rundown for Epizyme, Inc. (NASDAQ:EPZM) - Wall Street Hints and News - Earnings Review and Stock Rundown for Epizyme, Inc. (NASDAQ:EPZM)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Epizyme, Inc. (NASDAQ:EPZM) to post ...and more »
05/20/16 06:58 PMEpizyme Inc. (EPZM) Jumps 6.54% on May 20 - Equities.com - Epizyme Inc. (EPZM) Jumps 6.54% on May 20Equities.comEpizyme Inc. (EPZM) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 6.54% to $9.94, representing a gain of $0.61 per share. Some 202,923 shares traded hands on 1,736 trades, compared with an average daily ...and more »
05/20/16 03:50 PMEPIZYME, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/19/16 06:59 PMInsiders Are Buying Epizyme, Inc. (NASDAQ:EPZM) - Wall Street Hints and News - Insiders Are Buying Epizyme, Inc. (NASDAQ:EPZM)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Epizyme, Inc. (NASDAQ:EPZM) have increased their position in the stock by 104.94%. Insiders now own 26.47% of total outstanding shares. There are both legal and illegal types of insider trading. Illegal ...and more »
05/18/16 07:00 PMRevenue Update on Epizyme Inc(NASDAQ:EPZM) - Trade Calls - Revenue Update on Epizyme Inc(NASDAQ:EPZM)Trade CallsEpizyme Inc(NASDAQ:EPZM) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 9, 2016. Company reported revenue of $472.00K. Analysts estimated a revenue of $900.00K. Earnings per share were ...
05/18/16 12:04 PMEPIZYME, INC. Financials -
05/17/16 06:44 PMShare Recap and Earnings Focus on Epizyme, Inc. (NASDAQ:EPZM) - Wall Street Hints and News - Share Recap and Earnings Focus on Epizyme, Inc. (NASDAQ:EPZM)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Epizyme, Inc.and more »
05/17/16 06:44 PMEpizyme Inc. (EPZM) Jumps 6.44% on May 16 - Equities.com - Epizyme Inc. (EPZM) Jumps 6.44% on May 16Equities.comEpizyme Inc. (EPZM) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 6.44% to $9.58, representing a gain of $0.58 per share. Some 224,452 shares traded hands on 1,818 trades, compared with an average daily ...
About Epizyme

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPZM
  • CUSIP:
Key Metrics:
  • Previous Close: $10.44
  • 50 Day Moving Average: $10.83
  • 200 Day Moving Average: $11.32
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $563.64M
  • Current Quarter EPS Consensus Estimate: $-2.19 EPS
Additional Links:
Epizyme (NASDAQ:EPZM) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha